Form 8-K - Current report:
SEC Accession No. 0001610618-22-000017
Filing Date
2022-04-04
Accepted
2022-04-04 16:06:36
Documents
12
Period of Report
2022-03-30
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 FORM 8-K cdtx-20220330.htm   iXBRL 8-K 34011
  Complete submission text file 0001610618-22-000017.txt   174052

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cdtx-20220330.xsd EX-101.SCH 1903
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cdtx-20220330_lab.xml EX-101.LAB 25250
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cdtx-20220330_pre.xml EX-101.PRE 13142
6 EXTRACTED XBRL INSTANCE DOCUMENT cdtx-20220330_htm.xml XML 11270
Mailing Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121
Business Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121 858-752-6170
Cidara Therapeutics, Inc. (Filer) CIK: 0001610618 (see all company filings)

EIN.: 461537286 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36912 | Film No.: 22802146
SIC: 2836 Biological Products, (No Diagnostic Substances)